Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 70 - 95 |
| Updated: | 12/6/2018 |
| Start Date: | June 2016 |
| End Date: | September 2018 |
Effect of Mammalian Target of Rapamycin Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences
The ability to mount an effective immune response declines with age, leaving the elderly
increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug
to prevent transplant rejection, increases the lifespan and healthspan of mice and
ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in
laboratory animals. Investigators are conducting a translational trial to test whether
rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).
increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug
to prevent transplant rejection, increases the lifespan and healthspan of mice and
ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in
laboratory animals. Investigators are conducting a translational trial to test whether
rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).
Inhibition of the mTOR pathway by rapamycin (RAPA), an immunosuppressive drug used as adjunct
therapy in preventing solid organ allograft rejection, enhances longevity in mice.
Importantly, RAPA was efficacious even when initiated in relatively old animals. Thus, it has
been suggested that RAPA could be used therapeutically in humans to slow age-associated
pathologies. Indeed, improvements in cognition, control of tumorigenesis, and enhancing
certain aspects of immunity have been demonstrated in RAPA treated murine models. Moreover,
long-term RAPA delivery in older mice is associated with changes in immune reactivity not
evident in younger animals. Investigators propose to expand to a larger cohort of older
humans to test the hypothesis that RAPA treatment, even in very old individuals, will result
in simultaneous improvement in systems known to be negatively affected by aging.
Investigators will focus on the immune system, cognition, and physical parameters of healthy
aging, such as walking speed. Investigators will recruit healthy volunteers, aged 75-95
years, and randomize them to either RAPA or placebo, controlling for gender, ethnicity, and
age. These groups will be used to address the following specific aims: Aim 1. Assess general
parameters of immune health before and after RAPA treatment; these include serum inflammatory
cytokines, PBMC subsets (naïve vs memory T cells, TREGS, etc.), and polyclonal T cell
activation potential. Aim 2. Test the effects of RAPA treatment on responsiveness to a
vaccine challenge; both B cell (antibody) and T cell responses will be assessed. Aim 3.
Correlate immune function rejuvenation with cognitive and physical function measures in
subjects treated with RAPA or placebo. Aim 4. Collect pilot data on effect of RAPA on
cardiovascular function. Cognition will be assessed by three different testing tools (EXIT25,
SLUMS, and TAPS). Physical performance will be measured by grip strength and 40 foot timed
walks, parameters known to correlate with healthy aging. Measures of cardiovascular function
(Substudy D) using MRI of the heart to evaluate diastolic function and brain MRI to analyze
cerebral blood flow, with measures of pulse wave velocity and endothelial function using
laser doppler flowmetry will be performed. In addition to scoring positive outcomes,
investigators will assess whether there are adverse changes in clinical laboratory tests that
could compromise the safe use of RAPA therapeutically in older individuals. The long-term
goal is to assess whether RAPA is safe to use in an elderly population, while also being
efficacious in slowing, or even reversing, the aging process.
therapy in preventing solid organ allograft rejection, enhances longevity in mice.
Importantly, RAPA was efficacious even when initiated in relatively old animals. Thus, it has
been suggested that RAPA could be used therapeutically in humans to slow age-associated
pathologies. Indeed, improvements in cognition, control of tumorigenesis, and enhancing
certain aspects of immunity have been demonstrated in RAPA treated murine models. Moreover,
long-term RAPA delivery in older mice is associated with changes in immune reactivity not
evident in younger animals. Investigators propose to expand to a larger cohort of older
humans to test the hypothesis that RAPA treatment, even in very old individuals, will result
in simultaneous improvement in systems known to be negatively affected by aging.
Investigators will focus on the immune system, cognition, and physical parameters of healthy
aging, such as walking speed. Investigators will recruit healthy volunteers, aged 75-95
years, and randomize them to either RAPA or placebo, controlling for gender, ethnicity, and
age. These groups will be used to address the following specific aims: Aim 1. Assess general
parameters of immune health before and after RAPA treatment; these include serum inflammatory
cytokines, PBMC subsets (naïve vs memory T cells, TREGS, etc.), and polyclonal T cell
activation potential. Aim 2. Test the effects of RAPA treatment on responsiveness to a
vaccine challenge; both B cell (antibody) and T cell responses will be assessed. Aim 3.
Correlate immune function rejuvenation with cognitive and physical function measures in
subjects treated with RAPA or placebo. Aim 4. Collect pilot data on effect of RAPA on
cardiovascular function. Cognition will be assessed by three different testing tools (EXIT25,
SLUMS, and TAPS). Physical performance will be measured by grip strength and 40 foot timed
walks, parameters known to correlate with healthy aging. Measures of cardiovascular function
(Substudy D) using MRI of the heart to evaluate diastolic function and brain MRI to analyze
cerebral blood flow, with measures of pulse wave velocity and endothelial function using
laser doppler flowmetry will be performed. In addition to scoring positive outcomes,
investigators will assess whether there are adverse changes in clinical laboratory tests that
could compromise the safe use of RAPA therapeutically in older individuals. The long-term
goal is to assess whether RAPA is safe to use in an elderly population, while also being
efficacious in slowing, or even reversing, the aging process.
Inclusion Criteria: age 70-95
- participants will be in good health with all chronic diseases (hypertension, coronary
artery disease, etc.) clinically stable.
- participants must have adequate cognitive function to be able to give informed
consent. This will be established by enrolling participants with CLOX 1 scores of ≥10.
Exclusion Criteria:
- unstable ischemic heart disease
- clinically significant pulmonary disease
- history of immunodeficiency or receiving immunosuppressive therapy
- history of a coagulopathy or receiving a medical condition requiring anticoagulation
- an estimated glomerular filtration rate of <30ml/min
- uncontrolled hypercholesteremia >350mg/dl;
- uncontrolled hypertriglyceridemia >500mg/dl
- diabetes
- history of skin ulcers or poor wound healing
- smoking
- liver disease
- treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin)
We found this trial at
1
site
Click here to add this to my saved trials
